Rebus Holdings Inc (RBSH)

[Mrragu]

The inclusion of NSPX's drug mipsagargin in MediciNova's patent for treatment of Glioblastoma could development to be an important next step in the progress of the drug. It has always been thought that mipsagargin would be a first line treatment for brain cancer. Mipsagargin could hinder the progression of the disease, shrink the tumors or hold the cancer at bay until other treatments could be used. MediciNova's drug MN-166 (ibudilast) will be tested with a combination of various drug including mipsagargin. Genspera summarized their own trial #NCT02067156.

“We are very encouraged with the positive results from this interim Phase II trial that demonstrate the tolerability and indications of effectiveness of mipsagargin in advanced brain cancer patients,” said Craig Dionne, Ph.D., chief executive officer at GenSpera. “Mipsagargin is a first-in-class agent with a novel mechanism of action that is unlike any other drug being tested in patients with advanced brain cancer.”